- Home
- ASA vs VALN Comparison
ASA vs VALN Comparison
Compare ASA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASA
- VALN
- Stock Information
- Founded
- ASA 1958
- VALN 2012
- Country
- ASA United States
- VALN France
- Employees
- ASA N/A
- VALN N/A
- Industry
- ASA Precious Metals
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASA Industrials
- VALN Health Care
- Exchange
- ASA Nasdaq
- VALN Nasdaq
- Market Cap
- ASA 697.1M
- VALN 777.9M
- IPO Year
- ASA N/A
- VALN 2021
- Fundamental
- Price
- ASA $41.49
- VALN $8.93
- Analyst Decision
- ASA
- VALN Strong Buy
- Analyst Count
- ASA 0
- VALN 4
- Target Price
- ASA N/A
- VALN $15.75
- AVG Volume (30 Days)
- ASA 155.4K
- VALN 124.3K
- Earning Date
- ASA 09-26-2025
- VALN 11-06-2025
- Dividend Yield
- ASA 0.14%
- VALN N/A
- EPS Growth
- ASA 331.75
- VALN N/A
- EPS
- ASA 14.01
- VALN N/A
- Revenue
- ASA $3,923,667.00
- VALN $230,566,060.00
- Revenue This Year
- ASA N/A
- VALN $14.76
- Revenue Next Year
- ASA N/A
- VALN $24.11
- P/E Ratio
- ASA $2.96
- VALN N/A
- Revenue Growth
- ASA 66.52
- VALN 25.47
- 52 Week Low
- ASA $19.37
- VALN $3.62
- 52 Week High
- ASA $41.89
- VALN $12.25
- Technical
- Relative Strength Index (RSI)
- ASA 76.84
- VALN 49.17
- Support Level
- ASA $39.81
- VALN $8.33
- Resistance Level
- ASA $40.97
- VALN $9.46
- Average True Range (ATR)
- ASA 0.89
- VALN 0.35
- MACD
- ASA 0.27
- VALN -0.13
- Stochastic Oscillator
- ASA 92.75
- VALN 62.55
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.